TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: A novel cancer-selective target pathway with therapeutic opportunities

Oncotarget

Volumn 5, Issue 6, 2014, Pages 1609-1620

  D'Costa, Zenobia C ^a   Higgins, Catherine ^a   Ong, Chee Wee ^a   Irwin, Gareth W ^a   Boyle, David ^a   McArt, Darragh G ^a   McCloskey, Karen ^a   Buckley, Niamh E ^a   Crawford, Nyree T ^a   Thiagarajan, Lalitha ^a   Murray, James T ^b   Kennedy, Richard D ^a   Mulligan, Karl A ^c   Harkin, D Paul ^a   Waugh, David J J ^a   Scott, Chris J ^a   Salto Tellez, Manuel ^a   Williams, Richard ^a   Mullan, Paul B ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c Dental Training Agency   (United Kingdom)

Author keywords

Breast cancer; CST6; LGMN; TBX2

Indexed keywords

CATHEPSIN; CYSTATIN M; EARLY GROWTH RESPONSE FACTOR 1; LEGUMAIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR T BET; CST6 PROTEIN, HUMAN; CYSTEINE PROTEINASE; MESSENGER RNA; T BOX TRANSCRIPTION FACTOR; T-BOX DOMAIN PROTEIN 2;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL LINE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; CST6 GENE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME GLYCOSYLATION; ENZYME INHIBITION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TBX2 GENE; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CHROMATIN IMMUNOPRECIPITATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; GLYCOSYLATION; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYSTATIN M; CYSTEINE ENDOPEPTIDASES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS; TUMOR CELLS, CULTURED;

EID: 84904261428     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1707     Document Type: Article

References (45)

1. Chapman DL, Garvey N, Hancock S, Alexiou M, Agulnik SI, Gibson-Brown JJ, Cebra-Thomas J, Bollag RJ, Silver LM and Papaioannou VE. Expression of the T-box family genes, Tbx1-Tbx5, during early mouse development. Dev Dyn. 1996; 206(4):379-390.
2. Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ, Koh EY, Daley GQ, van Lohuizen M. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet. 2000; 26(3):291-299.
3. Prince S, Carreira S, Vance KW, Abrahams A and Goding CR. Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cancer Res. 2004; 64(5):1669-1674.
4. Vance KW, Carreira S, Brosch G and Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 2005; 65(6):2260-2268.
5. Ismail A and Bateman A. Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma. Cancer Lett. 2009.
6. Vance KW, Shaw HM, Rodriguez M, Ott S and Goding CR. The Retinoblastoma Protein Modulates Tbx2 Functional Specificity. Mol Biol Cell.
7. Redmond KL, Crawford NT, Farmer H, D'Costa ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP, Mullan PB. T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene. 2011; 29(22):3252-3262.
8. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget. 2(12):1352-1367.
9. Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschella G and Sala A. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget. 1(4):278-288.
10. Sotiropoulou G, Anisowicz A and Sager R. Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem. 1997; 272(2):903-910.
11. Ai L, Kim WJ, Kim TY, Fields CR, Massoll NA, Robertson KD and Brown KD. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 2006; 66(16):7899-7909.
12. Shridhar R, Zhang J, Song J, Booth BA, Kevil CG, Sotiropoulou G, Sloane BF and Keppler D. Cystatin M. suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene. 2004; 23(12):2206-2215.
13. Veena MS, Lee G, Keppler D, Mendonca MS, Redpath JL, Stanbridge EJ, Wilczynski SP and Srivatsan ES. Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. Genes Chromosomes Cancer. 2008; 47(9):740-754.
14. Qiu J, Ai L, Ramachandran C, Yao B, Gopalakrishnan S, Fields CR, Delmas AL, Dyer LM, Melnick SJ, Yachnis AT, Schwartz PH, Fine HA, Brown KD and Robertson KD. Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest. 2008; 88(9):910-925.
15. Pulukuri SM, Gorantla B, Knost JA and Rao JS. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene. 2009; 28(31):2829-2838.
16. Chen X, Cao X, Dong W, Xia M, Luo S, Fan Q and Xie J. Cystatin M. expression is reduced in gastric carcinoma and is associated with promoter hypermethylation. Biochem Biophys Res Commun. 2009; 391(1):1070-1074.
17. Zeeuwen PL, van Vlijmen-Willems IM, Olthuis D, Johansen HT, Hitomi K, Hara-Nishimura I, Powers JC, James KE, op den Camp HJ, Lemmens R, Schalkwijk J. Evidence that unrestricted legumain activity is involved in disturbed epidermal cornification in cystatin M/E deficient mice. Hum Mol Genet. 2004; 13(10):1069-1079.
18. Gawenda J, Traub F, Luck HJ, Kreipe H, von Wasielewski R. Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat. 2007; 102(1):1-6.
19. Murthy RV, Arbman G, Gao J, Roodman GD and Sun XF. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 2005; 11(6):2293-2299.
20. Fisher B, Redmond C, Wickerham DL, Wolmark N, Bowman D, Couture J, Dimitrov NV, Margolese R, Legault-Poisson S and Robidoux A. Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. Ann Intern Med. 1989; 111(9):703-712.
21. Jia L, Dourmashkin RR, Allen PD, Gray AB, Newland AC and Kelsey SM. Inhibition of autophagy abrogates tumour necrosis factor alpha induced apoptosis in human T-lymphoblastic leukaemic cells. Br J Haematol. 1997; 98(3):673-685.
22. Cheng T, Hitomi K, van Vlijmen-Willems IM, de Jongh GJ, Yamamoto K, Nishi K, Watts C, Reinheckel T, Schalkwijk J and Zeeuwen PL. Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J Biol Chem. 2006; 281(23):15893-15899.
23. Colbert JD, Plechanovova A and Watts C. Glycosylation directs targeting and activation of cystatin f from intracellular and extracellular sources. Traffic. 2009; 10(4):425-437.
24. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-404.
25. Ko E, Park SE, Cho EY, Kim Y, Hwang JA, Lee YS, Nam SJ, Bang S, Park J and Kim DH. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer. Breast Cancer Res. 2010; 12(6):R100.
26. Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V and Lianidou ES. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int J Cancer. 2009; 125(12):2887-2892.
27. Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W and Zhong XY. Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene. 2009; 28(33):2969-2978.
28. Lin HJ, Zuo T, Lin CH, Kuo CT, Liyanarachchi S, Sun S, Shen R, Deatherage DE, Potter D, Asamoto L, Lin S, Yan PS, Cheng AL, Ostrowski MC and Huang TH. Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res. 2008; 68(24):10257-10266.
29. Roll JD, Rivenbark AG, Jones WD and Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer. 2008; 7:15.
30. Demay F, Bilican B, Rodriguez M, Carreira S, Pontecorvi M, Ling Y and Goding CR. T-box factors: targeting to chromatin and interaction with the histone H3 N-terminal tail. Pigment Cell Res. 2007; 20(4):279-287.
31. Liu C, Sun C, Huang H, Janda K and Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003; 63(11):2957-2964.
32. Guo P, Zhu Z, Sun Z, Wang Z, Zheng X and Xu H. Expression of legumain correlates with prognosis and metastasis in gastric carcinoma. PLoS One. 2013; 8(9):e73090.
33. Wang L, Chen S, Zhang M, Li N, Chen Y, Su W, Liu Y, Lu D, Li S, Yang Y, Li Z, Stupack D, Qu P, Hu H and Xiang R. Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J Cell Biochem. 2012; 113(8):2679-2686.
34. Chen JM, Fortunato M, Stevens RA and Barrett AJ. Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol Chem. 2001; 382(5):777-783.
35. Jeang KT. Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? Oncotarget. 1(6):453-456.
36. Mancias JD and Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget. 2(12):1302-1306.
37. James KE, Gotz MG, Caffrey CR, Hansell E, Carter W, Barrett AJ, McKerrow JH and Powers JC. Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases). Biol Chem. 2003; 384(12):1613-1618.
38. Lee J and Bogyo M. Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain. Bioorganic & medicinal chemistry letters. 2012; 22(3):1340-1343.
39. Bajjuri KM, Liu Y, Liu C and Sinha SC. The Legumain Protease-Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity. ChemMedChem. 2012; 6(1):54-59.
40. Stern L, Perry R, Ofek P, Many A, Shabat D and Satchi-Fainaro R. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug Chem. 2009; 20(3):500-510.
41. Wu W, Luo Y, Sun C, Liu Y, Kuo P, Varga J, Xiang R, Reisfeld R, Janda KD, Edgington TS and Liu C. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res. 2006; 66(2):970-980.
42. Liao D, Liu Z, Wrasidlo W, Chen T, Luo Y, Xiang R and Reisfeld RA. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 7(6):665-673.
43. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst. 2007; 99(22):1683-1694.
44. Buckley NE, Hosey AM, Gorski JJ, Purcell JW, Mulligan JM, Harkin DP and Mullan PB. BRCA1 regulates IFNgamma signaling through a mechanism involving the type I IFNs. Mol Cancer Res. 2007; 5(3):261-270.
45. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R and Salto-Tellez M. CD133 expression predicts for nonresponse to chemotherapy in colorectal cancer. Mod Pathol. 23(3):450-457.